the saponins of the present invention may be obtained from the tree quillaja saponaria molina . the term “ saponin ” as used herein includes glycosidic triterpenoid compounds which produce foam in aqueous solution , have hemolytic activity in most cases , and possess immune adjuvant activity . the invention encompasses the saponin per se , as well as natural and pharmaceutically acceptable salts and pharmaceutically acceptable derivatives . the term “ saponin ” also encompasses biologically active fragments thereof . it has now been discovered that when doses of the qs - 7 and qs - 21 ( and / or qs - 21 - v1 and / or qs - 21 - v2 ) saponins that are suboptimal in achieving an antigen effect when administered independently of one another are coadministered with antigen , the combination produces a synergistic adjuvant effect that is considerably higher than the additive effect expected of such a combination . the invention concerns compositions comprising a combination of two or more substantially purified saponins from quillaja saponaria , used together in a mixture in doses that would be suboptimal if these saponins were used separately . the invention concerns compositions , such as immunologic compositions , comprising a combination of substantially pure saponins qs - 7 and either qs - 21 , qs - 21 - v1 , or qs - 21 - v2 or fractions or hydrolytic products thereof which may be linked to an antigen , and methods of using these compositions as vaccines and immune adjuvants . mixtures of qs - 21 , qs - 21 - v1 , and qs - 21 - v2 may also be used in combination with qs - 7 , as opposed to the individual saponins . the term “ immune adjuvant ,” as used herein , refers to compounds which , when administered to an individual or tested in vitro , increase the immune response to an antigen in the individual or test system to which said antigen is administered . some antigens are weakly immunogenic when administered alone or are toxic to the individual at concentrations which evoke immune responses in said individual . an immune adjuvant may enhance the immune response of the individual to the antigen by making the antigen more strongly immunogenic . the adjuvant effect may also lower the dose of said antigen necessary to achieve an immune response in said individual . by the term “ coadminister ” or “ coadministering ” is intended that each of at least two components be administered during a time frame wherein the respective periods of biological activity overlap . thus the term includes sequential as well as coextensive administration of the saponins and saponin compositions of the present invention . the immunogenic activity of the saponin compositions of the present invention may be determined by any of a number of methods known to those of ordinary skill in the art . the increase in titer of antibody against a particular antigen upon administration of the vaccines and / or adjuvants of the invention may be used as a criteria for immunogenic activity ( dalsgaard , k ., acta veterinia scandinavica 69 : 140 ( 1978 ); scott et al ., int . archs . allergy appl . immun . 77 : 409412 ( 1985 )). briefly , one such test involves injecting cd - 1 mice intradermally with a saponin composition / antigen conjugate which may be mixed with varying amounts of a potential adjuvant . sera is harvested from the mice two weeks later and tested by elisa for anti - immunogen antibody . the term “ substantially pure ” means substantially free from compounds normally associated with the saponin in its natural state and exhibiting constant and reproducible chromatographic response , elution profiles , and biologic activity . the term “ substantially pure ” is not meant to exclude artificial or synthetic mixtures of the saponin with other compounds . “ qs - 21 ” designates the mixture of components qs - 21 - v1 and qs - 21 - v2 which appear as a single peak on reverse phase hplc on vydac c4 column ( 5 μm particle size , 300 å pore , 4 . 6 mm id × 25 cml ) in 40 mm acetic acid in methanol / water ( 58 / 42 , v / v ). the component fractions are referred to specifically as qs - 21 - v1 and qs - 21 - v2 when describing experiments or results performed on the further purified components . there are multiple acceptable techniques for extraction and isolation of saponins from quillaja saponaria molina bark . acceptable procedures for purifying the saponins of the present invention from quillaja saponaria molina bark , measuring the saponins for immune adjuvant activity , and characterizing the substantially pure saponins are disclosed in u . s . pat . no . 5 , 057 , 540 and u . s . application ser . no . 07 / 906 , 880 ( allowed with issue fee paid , to issue as u . s . pat . no . 5 , 583 , 112 ), the entire contents of which are hereby incorporated by reference . aqueous extracts of quillaja saponaria bark are also available commercially . these are dark brown , foamy extracts that contain many compounds ( tannins , polyphenolics , saponins ) that can be analyzed by a method such as reversed phase hplc . an example of a reversed phase hplc analysis of a typical bark extract that is suitable for purification of saponins is shown in fig1 . the saponin adjuvants qs - 7 , qs - 17 , qs - 18 , and qs - 21 are shown , as “ a ”, “ b ”, c ”, and “ d ”, respectively . other minor saponins with adjuvant activity have also been described . partial purification to enrich the saponin fraction and to remove the majority of tannins and polyphenolics can be accomplished by dialysis of the extract against water through a 10 , 000 molecular weight membrane . the saponin fraction is retained . alternatively , an aqueous saponin extract can be pretreated with polyvinylpolypyrrolidone to remove high molecular weight tannins and polyphenolics through absorption of these compounds . residual tannins and polyphenolics can then be removed from the saponin fraction by diafiltration against water . the saponin fraction , which forms micelles , is retained by ultrafiltration membranes of 10 , 000 to 30 , 000 molecular weight cutoff pore size . this yields a partially purified extract that consists predominantly of diverse saponins . separation of saponins can be accomplished by chromatography in organic solvents or organic solvent / water mixtures . a separation of saponins on silica was described in u . s . pat . no . 5 , 057 , 540 . this yields saponins of intermediate purity ( enriched in an individual saponin , but less than substantially pure ). alternatively , other solvent systems on silica gel or the use of reverse phase chromatography can be used to accomplish the initial separation of saponins . this initial purification step can then typically be followed by reversed phase chromatography or similar hplc step to purify the saponins to near homogeneity . the substantially pure saponins useful in the present invention may also be isolated from fresh plant material consisting of substantially living cells as disclosed in wo 95 / 09179 , the entire contents of which is hereby incorporated by reference . for example , saponin extract may be recovered from plant cell material freshly extracted from approximately 15 year - old quillaja trees . dialyzed extract is then purified on an ion exchange column , e . g ., the de - 52 type , followed by sephadex g50 gel filtration . ultrafiltration may be used instead of gel filtration . the purified saponin composition is then subjected to rp - hplc analysis on a vydac c4 - column , eluted with 3045 % acetonitrile in a 0 . 15 % aqueous tfa - solution . the same procedure may be performed on plant cell material obtained by means of tissue culture or suspension cell culture . the saponin compositions of the invention are useful as vaccines which induce active immunity toward antigens in individuals . preferably , such individuals are humans ; however the invention is not intended to be so limiting . any animal which may experience the beneficial effects of the vaccines of the invention are within the scope of animals which may be treated according to the claimed invention . the saponin compositions of the present invention exhibit adjuvant effects when administered over a wide range of dosages and a wide range of ratios to the antigen being administered . in one embodiment , the saponin composition is administered in a ratio of adjuvant to immunogen ( w / w ) of 3 . 0 or less , preferably 1 . 0 or less . the saponin compositions of the invention may be administered either individually or admixed with other substantially pure adjuvants to achieve the enhancement of the immune response to an antigen . in the present invention , the two substantially pure saponins effective at producing a synergistic effect when coadministered are qs - 7 and qs - 21 . the combination of qs - 7 and qs - 21 may also be administered together with non - saponin adjuvants . such non - saponin adjuvants useful with the present invention are oil adjuvants ( for example , freund &# 39 ; s complete and incomplete ), liposomes , cholesterol , mineral salts ( for example , alk ( so 4 ) 2 , alna ( so 4 ) 2 , alnh 4 ( so 4 ), silica , alum , al ( oh ) 3 , ca 3 ( po 4 ) 2 , kaolin , and carbon ), poly - nucleotides ( for example , poly ic and poly au acids ), and certain natural substances or derivatives ( for example , wax d from mycobacterium tuberculosis , monophosphoryl lipid a ( salmonella minnesota ) as well as substances found in corynebacterium parvum , bordetella pertussis , and members of the genus brucella ), bovine serum albumin , diphtheria toxoid , tetanus toxoid , edestin , keyhole - limpet hemocyanin , pseudomonal toxin a , choleragenoid , cholera toxin , pertussis toxin , viral proteins , and eukaryotic proteins such as interferons , interleukins , or tumor necrosis factor . such proteins or active fragments may be obtained from natural or recombinant sources according to methods known to those skilled in the art . other known immune - potentiating macromolecules which may be used in the practice of the invention include , but are not limited to , polysaccharides , dna / rna nucleotides , trna , nonmetabolizable synthetic polymers such as polyvinyl - amine , polymethacrylic acid , polyvinylpyrrolidone , mixed polycondensates ( with relatively high molecular weight ) of 4 ′ 4 ′- diaminodiphenyl - methane - 3 , 3 ′- dicarboxylic acid and 4 - nitro - 2 - aminobenzoic acid ( see sela , m ., science 166 : 1365 - 1374 ( 1969 )) or glycolipids , lipids or carbohydrates . the saponin compositions of the present invention may be directly linked to the antigen or may be linked via a linking group as disclosed in u . s . pat . no . 5 , 057 , 540 and u . s . application ser . no . 07 / 906 , 880 ( allowed with issue fee paid , to issue as u . s . pat . no . 5 , 583 , 112 ), the entire contents of which are hereby incorporated by reference . the saponin compositions of the present invention may be utilized to enhance the immune response to any antigen . typical antigens suitable for the immune - response provoking compositions of the present invention include antigens derived from any of the following , as well as other sources : viruses , such as influenza virus , herpes simplex virus , feline leukemia virus , feline immunodeficiency virus , hiv - 1 , hiv - 2 , rabies virus , measles virus , hepatitis b virus , or hoof and mouth disease virus ; bacteria , such as streptococcus pneumoniae , staphylococcus aureus , escherichia coli , bacillus anthracis , corynebacterium diphtheriae , borrelia burgdorferi , mycobacterium tuberculosis , or granulocytic and monocytic ehrlichia ; protozoans , such as babeosis bovis or plasmodium ; cancer , e . g ., melanoma ; parasites , prions ( e . g . mad - cow disease ), and auto immune disease . the antigens may be proteins , peptides , monosaccharides , polysaccharides , lipopolysaccharides , lipoproteins , and dna or rna nucleotides . the proteins , peptides and nucleic acids may be purified from a natural source , synthesized by means of solid phase synthesis , or may be obtained by means of recombinant genetics . administration of the saponin compositions useful in the method of present invention may be by parenteral , intravenous , intramuscular , subcutaneous , intranasal , oral , or any other suitable means . the dosage administered may be dependent upon the species , age , weight , kind of concurrent treatment , if any , and nature of the antigen administered . the saponin compositions of the present invention may be administered in any therapeutically effective dosage . a therapeutically effective dosage is any dosage that tends to stimulate an immune response to antigen . preferably , the novel saponin compositions of the present invention are adminstered to a human patient in a dosage of from 5 μg - 25 μg qs - 21 , and from 100 μg to 400 μg qs - 7 . other therapeutic compositions that may fall outside of this range ( e . g ., due to the use of different purified saponins , antigen , or species ) may be defined by determining suboptimal and optimal doses of each of the two purified saponins , used alone , in a dose - ranging study with a given antigen in a given species . the therapeutic composition would consist of dosages of two or more saponins where each are combined in doses in the suboptimal range when used individually , but where the same doses in a mixture in a composition provide the desired activity . the maximum possible adjuvant effect for an adjuvant such as qs - 21 , qs - 7 , or other purified saponins can be defined by the use of a dose response curve for a given antigen or species . this curve will typically define doses that yield the maximum possible enhancement of immune response . the difference between this maximum immune response and the immune response to a nonadjuvanted formulation can be defined as a value “ x ”. this value “ x ” can be measured as an antigen - specific antibody titer ( non - log transformed ) and / or as a % of cytolytic activity due to cytotoxic t lymphocytes at a given effector : target ratio . a suboptimal adjuvant response will typically be 20 % or less of “ x ”. the desired adjuvant response will typically be at least 50 % or more of “ x ”. the effective saponin compositions useful in the method of the present invention may be employed in such forms as capsules , liquid solutions , suspensions or elixirs for oral administration , or sterile liquid forms such as solutions or suspensions . any inert carrier is preferably used , such as saline , or phosphate - buffered saline , or any such carrier in which the compounds used in the method of the present invention have suitable solubility properties for use in the methods of the present invention . the saponin compositions of the present invention can be combined successfully with vehicle adjuvants . for example , the saponin compositions may be combined in antigen / saponin / sterol ( preferably cholesterol ) immune - stimulating complexes ( iscoms ) and iscom matrices as disclosed in morein , b . et al ., nature 308 : 457 ( 1984 ), the entire contents of which are hereby incorporated by reference . an acceptable procedure for preparation of iscoms comprises solubilization of amphipathic antigen in preferably nonionic detergent followed by the addition of quillaja saponins , e . g ., qs - 21 and qs - 7 , a sterol , e . g ., cholesterol , and phosphatidylcholine . in the presence of amphipathic antigen , iscom particles are formed on removal of the detergent . if no antigen is present in the mixture , iscom matrix is formed . iscom - borne antigen induces an enhanced , cell - mediated immune response , delayed type hypersensitivity reaction , and cytotoxic t - lymphocyte ( ctl ) response under mhc class i restriction . the saponin compositions of the present invention may also be encapsulated within polymeric microspheres . for example , polymeric microspheres , such as poly ( lactic - co - glycolic ) acid ( plga ), have been shown to be a compatible combination with qs - 21 ( cleland , j . l . et al ., aids res . hum . retroviruses 10 ( s2 ): s21 ( 1994 ). saponins have also been combined with liposomes and liposomes prepared from natural and synthetic lipids according to u . s . pat . no . 4 , 235 , 877 to fullerton . also , liposomes containing intercalated quil a have been used as vehicles for hydrophilic antigens ( lipford , g . b . et al ., vaccine 12 ( 1 ): 73 ( 1994 ). the saponin compositions of the present invention may also be used in a kit for the immunization of an individual comprising a carrier compartmentalized to receive in close confinement therein one or more container means wherein a first container contains a saponin composition of the invention . the kit may also include at least one other container means which contain a saponin adjuvant or other adjuvant as described herein . having now generally described the invention , the same may be further understood by reference to the following examples , which are not intended to be limiting unless so expressly stated . 20 grams of lyophilized , dialyzed quillaja saponaria extract was dissolved in 150 mls of a mixture of 62 % chloroform , 32 % methanol , 6 % water , and 0 . 23 % acetic acid ( v / v / v / v ). a total volume of 100 ml was loaded onto a 10 cm diameter column loaded with 450 g silica ( em lichroprep , si 60 , 40 - 63 micron ) in the same solvent mixture . the separate qs - 21 and qs - 7 fractions were identified by reversed - phase hplc analysis , pooled , and dried by rotary evaporation followed by lyophilization . the total yield of qs - 21 intermediate was 3 . 2 grams of approximately 51 % purity by reversed phase hplc . qs - 7 eluted in a later fraction ( 0 . 66 grams of 17 % purity ). qs - 21 intermediate , prepared in example 1 , was further purified by preparative reversed phase hplc on a vydac c18 column ( 10 micron particle size , 300 angstrom pore size , 25 cm length , 2 . 2 cm diameter ). a 100 mg / ml solution of qs - 21 intermediate was prepared in 38 % actonitrile / 62 % water / 0 . 15 % trifluoroacetic acid ( v / v / v ). a 20 mg aliquot was then separated on the vydac column under isocratic chromatographic conditions in 38 % acetonitrile / 62 % water / 0 . 15 % trifluoroacetic acid . sixteen chromatography runs under identical isocratic chromatography runs were carried out . fractions that yielded substantially pure qs - 21 ( from in - process reversed phase hplc analysis ) were collected and pooled for a total volume of 930 ml . this was diluted to 1860 ml by the addition of hplc grade water . the diluted pool was loaded onto a vydac c18 column ( 20 - 30 micron , 15 cm length × 2 . 5 cm internal diameter ) equilibrated in water . the diluted pool was loaded onto the column at 10 ml / minute , run in 100 % water for an additional 30 minutes at 10 ml / minute , and then the qs - 21 was eluted with a linear gradient from 100 % water to 100 % methanol over 60 minutes . the qs - 21 eluted as a single peak . the qs - 21 / methanol / water mixture was transferred to a lyophilization flask , evaporated under a steady stream of nitrogen to remove methanol , and freeze - dried . the final yield was 59 mg of qs - 21 of approximate 98 % purity . a suitable aqueous extract of quillaja saponaria is adsorbed to polyvinylpolypyrrolidone ( pvpp ) at a ratio of 120 grams of pvpp per liter of 10 % extract ( w / v ). the pvpp binds and separates tannins and polyphenolics from the soluble saponin fraction . the pvpp is removed by an appropriate method such as centrifugation or filtration . this is then followed by membrane filtration of the treated extract to remove small particulates . a sample is analyzed via in - process hplc analysis and comparison to a qs - 21 standard curve for determination of qs - 21 concentration . the saponins in the pvpp - treated extract are further concentrated by ultrafiltration ( through a 30 , 000 dalton molecular weight cutoff membrane ) to an approximate concentration of 8 to 12 grams per liter . the retentate , containing the saponin fraction , is then diafiltered against 5 volumes of purified water . the diafiltration retentate is then collected , analyzed for qs - 21 content by in - process reversed - phase hplc analysis , and is diluted to a final qs - 21 concentration of 7 to 9 grams per liter . the actual qs - 21 concentration is determined at this point by in - process hplc analysis and comparison to a qs - 21 standard curve for determination of qs - 21 concentration . this extract is then diluted by addition of acetonitrile to a final 30 % acetonitrile ( v / v ) concentration , centrifuged at 10 , 000 × g for 30 min , and the precipitate is discarded . the filtered supernatant is further purified by consecutive preparative hplc runs on a phenyl hplc resin in a stainless steel column ( 25 cm length column with an additional 5 cm length guard column ) equilibrated in a solvent consisting of 30 % acetonitrile , 70 % water , and 0 . 2 % acetic acid . the qs - 21 peak is eluted by running a linear gradient from 30 % to 39 % acetonitrile over 19 column volumes followed by a linear gradient from 39 % to 90 % acetonitrile over 1 column volume . the fractions containing qs - 21 are collected . this step yields qs - 21 of approximately 60 - 75 % purity . this qs - 21 fraction is further purified by repetitive , automated preparative hplc on a phenyl hplc resin ( spherical ) packed into a stainless steel column ( 25 cm length with a 5 cm length guard column ) and equilibrated in 20 % acetonitrile , 0 . 2 % acetic acid . the qs - 21 peak is eluted with a linear gradient from 20 to 28 % acetonitrile , 0 . 2 % acetic acid over 1 . 7 column volumes followed by a linear gradient from 28 % to 35 % acetonitrile over 3 . 3 column volumes followed by a linear gradient from 35 % to 38 . 5 % acetonitrile over 14 column volumes . the fractions containing qs - 21 are collected . the qs - 21 pool is diluted by addition of a minimum of 0 . 5 volumes of hplc grade water . the qs - 21 fraction is adsorbed to a column of 10 cm length containing c8 resin ( 15 - 25 micron particle size ). the column is rinsed with at least one column volume of water . qs - 21 is eluted from the resin by a linear methanol gradient 90 to 100 %. the qs - 21 eluate is collected , evaporated to near dryness in a rotary evaporator under vacuum , and dried further on a lyophilizer . the qs - 21 powder is then resuspended in a small volume of hplc grade water ( 8 to 12 g qs - 21 per 100 ml water ) and relyophilized to dryness . the final product is ≧ 98 % pure by reversed - phase hplc . qs - 7 intermediate , prepared as described in example 1 , was further purified on a waters c18 column . a 100 mg / ml solution of qs - 7 intermediate was dissolved in water . twenty mg of this solution was eluted on c18 ( 0 . 78 cm id × 30 cm length , 10 micron ) in a linear gradient of 80 % water / 20 % acetonitrile / 0 . 15 % trifluoroacetic acid to 40 % water / 60 % acetonitrile / 0 . 15 % trifluoroacetic acid over 75 minutes at a 2 ml / minute flow rate . a total of four runs were made and the qs - 7 fractions were combined for a total of 19 mg of approximate 54 % purity . this preparation was dissolved at 4 mg / ml in water and further purified by isocratic hplc on the same column , equilibrated in 67 % water / 33 % acetonitrile / 0 . 15 % trifluoroacetic acid . the collected fractions were diluted with an equal volume of water and adsorbed to c18 resin ( 20 - 30 micron ) in a buchner funnel , and washed with 90 ml water . the qs - 7 was then eluted with 40 ml methanol . the methanol was evaporated under a stream of nitrogen , the qs - 7 was redissolved in water , and lyophilized , yielding a total of 8 mg of purified qs - 7 . other reversed phase resins , solvents , and separation gradients have been shown to be suitable for purification of qs - 7 and qs - 21 as well as other saponins from q . saponaria ( kensil , j . immunol . 146 : 431 - 437 ( 1991 )). qs - 7 can be obtained from diafiltered , pvpp - treated quillaja saponaria extract which is then adjusted to 25 % acetonitrile / 75 % water / 0 . 2 % acetic acid ( v / v / v ). this extract is further purified by consecutive preparative hplc runs on a phenyl hplc resin ( 10 micron particle size , 100 angstrom pore size ) in a stainless steel column ( 25 cm length column ) equilibrated in a solvent consisting of 20 % acetonitrile , 75 % water , and 0 . 2 % acetic acid . the qs - 7 peak is eluted by running a linear gradient from 25 % to 36 % acetonitrile over 11 column volumes . the qs - 7 fractions are collected . this step yields qs - 7 of approximately 50 to 60 % purity . the pool from these column runs is then diluted to 28 % acetonitrile / 72 % water / 0 . 2 % acetic acid by addition of 0 . 2 % acetic acid in water ( v / v ). the qs - 7 fraction is then further purified by isocratic chromatography on c8 hplc resin ( 10 micron particle size , 100 angstrom pore size in a 25 cm length column ) equilibrated in a solvent consisting of 31 % acetonitrile / 69 % water / 0 . 2 % acetic acid ( v / v / v ). the qs - 7 fractions are collected . the qs - 7 fraction is diluted by addition of 2 volumes of water for injection . the qs - 7 fraction is adsorbed to a column of 10 cm length containing c8 resin ( 15 - 25 micron particle size ). a linear gradient of 5 to 50 % t - butyl alcohol is used to elute qs - 7 from the column . the fractions containing qs - 7 are collected . these fractions are directly lyophilized to yield a white powder . this process yields a qs - 7 of ≧ 95 % purity by reversed - phase hplc . distinct saponins can be identified by mass spectrometry . fig2 a shows the analysis of qs - 21 by fast atom bombardment mass spectroscopy in the negative mode . the predominant pseudomolecular ion is 1988 , corresponding to m / z =[ m - h ] − where m = c 92 o 46 h 148 . fig2 b shows the spectrum of the qs - 7 peak by fast atom bombardment mass spectrometry . the predominant pseudomolecular ion is 1862 , corresponding to [ m - h ] − . one formula consistent with this structure is c 83 o 46 h 130 . the saponins from q . saponaria are acylated bisdesmodic triterpene glycosides . the structure of qs - 21 has been determined by 2 - d 1 h and 13 c - nmr ( jacobsen , n . e . et al ., carbohydrate research , volume 280 : 1 - 14 ( 1996 )). this structure is shown in fig3 b . a proposed structure for qs - 7 is shown in fig3 a . immunologic compositions comprising one or more substantially pure quillaja saponaria saponin fractions and methods of using such compositions as immune adjuvants were previously disclosed in kensil et al . u . s . pat . no . 5 , 057 , 540 and in copending u . s . patent application ser . no . 07 / 906 , 880 ( allowed with issue fee paid , to issue as u . s . pat . no . 5 , 583 , 112 ), the entire disclosures of which are hereby incorporated by reference . kensil , c . r . et al ., vaccine 2 : 273 - 281 ( 1993 ) teaches that doses below 2 . 5 μg qs - 21 are ineffective as adjuvants for is raising an antibody response to the ovalbumin antigen in mice . similarly , newman , m . et al ., j . immunol . 148 : 2357 - 2362 ( 1992 ) shows a corresponding qs - 21 dose response curve for the cytotoxic t lymphocyte ( ctl ) response to ovalbumin . again , at 2 . 5 μg or lower , the response in mice is minimal . the present inventors have now discovered that two substantially pure saponins unexpectedly produce a synergistic adjuvant effect when combined in suboptimal doses . the two saponins which produce a synergistic response when combined at suboptimal doses are qs - 7 and qs - 21 . briefly , five mixtures of suboptimal doses of qs - 7 and qs - 21 were tested for their ability to produce a synergistic response . it was expected that the effect would be an additive adjuvant effect . all experiments were carried out in c57bl / 6 mice ( female , 8 - 12 weeks of age ). the synergistic adjuvant - effect of the qs - 21 / qs - 7 mixtures was assessed by two parameters : ( 1 ) the ability of these mixtures to improve antibody titers to a subunit antigen , ovalbumin , in mice ; and ( 2 ) the ability of these mixtures to improve an ovalbumin - specific cytotoxic t lymphocyte ( killer cell ) response in mice . the experimental techniques were the following . the mice were immunized subcutaneously at week 1 , 3 , and 5 with 0 . 2 ml of the indicated formulations in phosphate - buffered saline . mice were immunized in groups of five . sera and spleens were harvested at weeks 7 to 9 . sera was assayed for anti - ovalbumin antibody response by enzyme immunoassay . briefly , a 96 well immulon plate was coated with 10 μg / ml ovalbumin in phosphate - buffered saline ( pbs ) overnight at 4 ° c . these plates were blocked with 10 % normal goat serum in pbs ( diluent ) for one hour at room temperature . serial 1 : 10 dilutions of serum were made in diluent and were incubated on the plates for one hour at room temperature or overnight at 4 ° c . an enzyme conjugate of anti - mouse igg ( or anti - mouse igg subclass ) was diluted in diluent and incubated on the plate . a calorimetric enzyme substrate , tetramethylbenzidine , was used to assay for binding of anti - ovalbumin antibody . spleens from immunized mice were used to assay for the cytotoxic t lymphocyte ( ctl ) response . the effector cells for the ( ctl ) assay were splenic mononuclear cells from the harvested spleens . the antigen - positive target cells for the assay were e . g7 - ova cells , which are an mhc class ii antigen - negative el4 mouse cell line , transfected with the ovalbumin gene . this cell line expresses an ovalbumin peptide on mhc class i antigen and hence is a target for ovalbumin - specific cytotoxic t lymphocytes ( moore , m ., et al ., cell 54 : 777 ( 1988 )). el4 cells were used as an ovalbumin - negative target cell line . prior to assay , splenic mononuclear cells were stimulated with antigen to induce maturation of precursor ctl in the effector cell population . the antigens used for stimulation were mitomycin c treated e . g7 - ova cells ( incubated with spleen cells at a ratio of 20 : 1 spleen cells : e . g7 - ova cells ) or denatured ovalbumin ( 25 μg / ml ). bulk cell culture was carried out in a 2 ml volume at 10 6 / ml , using supplemented rpmi 1640 medium , at 37 ° c . cells were recovered after a six day culture , resuspended in fresh media , and used in the ctl assay . target cells ( e . g7 - ova or el4 ) were prepared for the ctl assay by labeling with na 2 cro 4 ( 51 cr ) by incubation for 1 hour at 37 ° c . in rpmi 1640 culture media with 0 . 3 m sucrose . a standard cytotoxicity assay was used with 10 4 target cells per well and a titration of effector : target ratios of 25 : 1 , 12 : 1 6 : 1 , and 3 : 1 . the experimental data was converted to % lysis . the % of lysis of el4 cells was subtracted from the lysis of e . g7 - ova cells to determine the % of antigen - specific lysis . first , suboptimal doses of the saponin adjuvants qs - 7 and qs - 21 were identified . fig4 and 5 show that 0 . 625 μg and 1 . 25 μg of qs - 21 are ineffective in stimulating a ctl response . in contrast , a dose of 20 μg of qs - 21 is highly effective in stimulating a ctl response . fig4 and 5 show that 10 and 20 μg of qs - 7 are ineffective in stimulating a strong ctl response . these suboptimal doses of qs - 21 and qs - 7 were then combined as follows : mixture qs - 21 qs - 7 1 0 . 625 μg 10 μg 2 1 . 25 μg 10 μg 3 0 . 625 μg 20 μg 4 1 . 25 μg 20 μg unexpectedly , these mixtures yielded considerably higher cytotoxic t - lymphocyte responses than predicted by simple addition of the response to the doses of qs - 21 and qs - 7 . the response is most dramatic at the lower dose of qs - 7 ( 10 μg ). the response for these four mixtures is shown in fig4 - 7 . these mixtures also yielded unexpectedly higher antibody titers to ovalbumin , particularly in the igg2b subclass . the mean log 10 titer from an average of five mice receiving these mixtures , compared to suboptimal individual doses , is shown in fig8 . for example , neither 10 μg qs - 7 or 0 . 625 μg qs - 21 , individually , yields a titer that is higher than no adjuvant , showing that these doses are suboptimal . however , the combination of 0 . 625 μg qs - 21 with 10 μg of qs - 7 yields an increase of 1 log 10 unit in titer ( 10 fold increase in titer ), indicating that the combination of the two is an effective adjuvant mixture that yields a response comparable to a known optimal dose of qs - 21 ( 20 μg ). the synergistic effect was also observed in another experiment using the same experimental model . in that experiment , a mixture of 1 . 25 μg of qs - 21 and 18 . 8 μg qs - 7 was compared to 1 . 25 μg qs - 21 and 20 μg qs - 7 , respectively . the mixture produced a higher cytotoxic t - lymphocyte response and serum antibody response than predicted from these saponins alone ( fig9 - 10 ).
the present invention is in the field of medicinal chemistry . in particular , the invention is related to vaccines comprising novel combinations of saponin adjuvants , to pharmaceutical compositions and vaccines comprising these novel combinations , to methods of using these novel combinations to enhance the immune response of an individual to an antigen , and to the use of the novel combinations to increase the immunogenicity of vaccines .